Form 4: Tandem Diabetes Care: Executive Stock Transactions

Jean-Claude Kyrillos, EVP & COO of Tandem Diabetes Care, reported stock transactions including RSU vesting and ESPP purchases.

Summary

• Jean-Claude Kyrillos, Executive Vice President & Chief Operating Officer of Tandem Diabetes Care Inc., reported several stock transactions on May 15, 2026.
• 4,038 shares of common stock were acquired with a transaction code 'M', valued at $0, to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). These RSUs were awarded on May 30, 2025, under the 2023 Long-Term Incentive Plan.
• 2,139 shares were disposed of with a transaction code 'F' at a price of $12.82 per share.
• 434 shares were acquired with a transaction code 'A' at a price of $10.90 per share, as part of the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP) for the purchase period ending May 15, 2026.
• Following these transactions, Kyrillos beneficially owns 28,105 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine executive stock transactions related to compensation and employee plans, with no significant positive or negative strategic implications.

Positives

• Acquisition of shares through the Employee Stock Purchase Plan (ESPP) indicates employee participation and potential for wealth accumulation.
• Vesting of restricted stock units (RSUs) suggests achievement of performance or service milestones, aligning executive interests with the company.
• The acquisition of shares for tax withholding purposes on RSU vesting, while a disposition of some shares, is a standard part of equity compensation.

Negatives

• A disposition of 2,139 shares occurred, though the reason is not specified beyond a transaction code 'F'.

Risks

• The disposition of shares by a key executive could be interpreted negatively by the market, although the context of RSU vesting and ESPP participation is important.
• The vesting schedule for RSUs indicates that a significant portion of the award vests on May 15, 2026, with the remainder vesting quarterly over the next eight quarters, implying a phased release of equity.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a report of past transactions.

Management Comments

• The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2025, through May 15, 2026. This transaction is also exempt under Rule 16b-3(c).

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for executives and directors of publicly traded companies, providing transparency into their stock holdings and transactions. This filing for Tandem Diabetes Care (TNDM) is typical for reporting equity compensation events and employee stock purchase plan participation.

Stakeholder Impact

• Shareholders: Increased transparency into executive stock ownership and potential selling pressure (though mitigated by the nature of the transactions).
• Employees: The ESPP participation by a senior executive may signal confidence in the company's stock.
• Management: Standard reporting of equity compensation realization.

Next Steps

• The remaining shares subject to the RSU award will vest in eight (8) equal quarterly installments after May 15, 2026.

Key Dates

Keywords

Form 4, SEC Filing, Tandem Diabetes Care, TNDM, Jean-Claude Kyrillos, Stock Transaction, Executive Compensation, Restricted Stock Units, RSU Vesting, Employee Stock Purchase Plan, ESPP, Beneficial Ownership